Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Ohio State University Comprehensive Cancer Center
Modality
UNKNOWN
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
72High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07410559CT.gov Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07015853CT.gov ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation | — | Not Yet Recruiting | — | — | — |
NCT07570368CT.gov Targeting Stress-Driven Inflammatory and Angiogenic Pathways With Brief ACT to Enhance Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07217990CT.gov Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07372079CT.gov Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy | — | Not Yet Recruiting | — | — | — |
NCT07340541CT.gov Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies | — | Recruiting | — | — | — |
NCT06324240CT.gov Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT06492759CT.gov High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT07407920CT.gov Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial | — | Active Not Recruiting | — | — | — |
NCT07016399CT.gov Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC | — | Recruiting | — | — | — |
Show 237 more trialsShow fewer
NCT06606730CT.gov Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT06914440CT.gov Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer | — | Recruiting | — | — | — |
NCT06604858CT.gov Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT06797635CT.gov Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) | — | Recruiting | — | — | — |
NCT06876636CT.gov Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT06618287CT.gov A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05539365CT.gov Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer | — | Withdrawn | — | — | — |
NCT06500208CT.gov Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC | — | Recruiting | — | — | — |
NCT06513364CT.gov Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer | — | Completed | — | — | — |
NCT05741164CT.gov Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT06532812CT.gov TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer | — | Recruiting | — | — | — |
NCT06470633CT.gov To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT05485766CT.gov Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT06404463CT.gov QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06351332CT.gov ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC | — | Terminated | — | — | — |
NCT06389006CT.gov To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer | — | Recruiting | — | — | — |
NCT05756166CT.gov Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer | — | Terminated | — | — | — |
NCT06246968CT.gov A Study of Pembrolizumab and Cryoablation in People With Breast Cancer | — | Recruiting | — | — | — |
NCT06144944CT.gov Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT06103864CT.gov A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | — | Recruiting | — | — | — |
NCT05491226CT.gov Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation | — | Recruiting | — | — | — |
NCT06112379CT.gov A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05900206CT.gov Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer | — | Recruiting | — | — | — |
NCT05318469CT.gov Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT06107673CT.gov Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC） | — | Recruiting | — | — | — |
NCT05673200CT.gov Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer | — | Recruiting | — | — | — |
NCT05929768CT.gov Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT05983094CT.gov Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06227117CT.gov Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer | — | Recruiting | — | — | — |
NCT05852691CT.gov A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05914753CT.gov Evaluating Xihuang Pill to Improve the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer | — | Unknown | — | — | — |
NCT05812807CT.gov Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | — | Recruiting | — | — | — |
NCT05675579CT.gov A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) | — | Active Not Recruiting | — | — | — |
NCT05422794CT.gov Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer | — | Recruiting | — | — | — |
NCT05020860CT.gov Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer | — | Recruiting | — | — | — |
NCT05787587CT.gov A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06009627CT.gov Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients | — | Completed | — | — | — |
NCT04789096CT.gov Tucatinib Together With Pembrolizumab and Trastuzumab | — | Terminated | — | — | — |
NCT05953909CT.gov A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01). | — | Unknown | — | — | — |
NCT05576077CT.gov A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04616248CT.gov In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04348747CT.gov Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer | — | Recruiting | — | — | — |
NCT05431582CT.gov Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors | — | Withdrawn | — | — | — |
NCT05645380CT.gov Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC | — | Active Not Recruiting | — | — | — |
NCT05629585CT.gov A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) | — | Active Not Recruiting | — | — | — |
NCT05093387CT.gov SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer | — | Withdrawn | — | — | — |
NCT05582499CT.gov Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | — | Recruiting | — | — | — |
NCT05491694CT.gov To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer | — | Unknown | — | — | — |
NCT04512261CT.gov TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases | — | Withdrawn | — | — | — |
NCT05395052CT.gov FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05070247CT.gov A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT03492918CT.gov Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16) | — | Unknown | — | — | — |
NCT05269381CT.gov Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05177796CT.gov Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer | — | Withdrawn | — | — | — |
NCT05131893CT.gov Neoadjuvant Treatment of Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT05287308CT.gov Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study | — | Not Yet Recruiting | — | — | — |
NCT05163223CT.gov Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer | — | Terminated | — | — | — |
NCT05681728CT.gov A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer | — | Unknown | — | — | — |
NCT05203445CT.gov A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05233696CT.gov Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC | — | Withdrawn | — | — | — |
NCT05159778CT.gov Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA) | — | Completed | — | — | — |
NCT04849364CT.gov Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer | — | Terminated | — | — | — |
NCT05728268CT.gov Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index | — | Recruiting | — | — | — |
NCT04136782CT.gov Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer | — | Recruiting | — | — | — |
NCT04137640CT.gov Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy | — | Unknown | — | — | — |
NCT05165225CT.gov Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial | — | Active Not Recruiting | — | — | — |
NCT05656079CT.gov To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study | — | Unknown | — | — | — |
NCT04717531CT.gov Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer | — | Unknown | — | — | — |
NCT04683679CT.gov A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer | — | Recruiting | — | — | — |
NCT04872985CT.gov Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04190056CT.gov Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer | — | Terminated | — | — | — |
NCT04660929CT.gov CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | — | Unknown | — | — | — |
NCT04373031CT.gov Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04418219CT.gov Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT04683445CT.gov Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer | — | Unknown | — | — | — |
NCT03841747CT.gov Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT04585750CT.gov The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | — | Recruiting | — | — | — |
NCT04448886CT.gov Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC | — | Active Not Recruiting | — | — | — |
NCT04140526CT.gov Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | — | Active Not Recruiting | — | — | — |
NCT03982004CT.gov Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT03988036CT.gov A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1) | — | Completed | — | — | — |
NCT04251169CT.gov Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression | — | Terminated | — | — | — |
NCT04468061CT.gov Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | — | Recruiting | — | — | — |
NCT04348916CT.gov Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors | — | Terminated | — | — | — |
NCT03971045CT.gov Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer | — | Recruiting | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT04290793CT.gov Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04244552CT.gov A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | — | Terminated | — | — | — |
NCT04042701CT.gov DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04335669CT.gov NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC | — | Active Not Recruiting | — | — | — |
NCT03546686CT.gov Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04066790CT.gov Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer | — | Terminated | — | — | — |
NCT01907529CT.gov A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer | — | Unknown | — | — | — |
NCT03952325CT.gov Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC | — | Terminated | — | — | — |
NCT03609047CT.gov Adjuvant Palbociclib in Elderly Patients With Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03894007CT.gov Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer | — | Terminated | — | — | — |
NCT04264468CT.gov Correlation Between Molecular Typing and Neoadjuvant Chemotherapy in Breast Cancer Patients Based on Mammaprint/Blueprint Test | — | Unknown | — | — | — |
NCT03789097CT.gov Vaccination With Flt3L, Radiation, and Poly-ICLC | — | Completed | — | — | — |
NCT03644589CT.gov Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer | — | Withdrawn | — | — | — |
NCT03632941CT.gov A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer | — | Terminated | — | — | — |
NCT03747120CT.gov Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP] | — | Active Not Recruiting | — | — | — |
NCT04172259CT.gov ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC | — | Active Not Recruiting | — | — | — |
NCT03599453CT.gov Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer | — | Completed | — | — | — |
NCT03725059CT.gov Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) | — | Active Not Recruiting | — | — | — |
NCT03756090CT.gov The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer | — | Unknown | — | — | — |
NCT03647280CT.gov The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast Cancer | — | Unknown | — | — | — |
NCT03449238CT.gov Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients | — | Recruiting | — | — | — |
NCT03435952CT.gov Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT | — | Active Not Recruiting | — | — | — |
NCT03556358CT.gov Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer | — | Completed | — | — | — |
NCT03387553CT.gov HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer | — | Completed | — | — | — |
NCT03432741CT.gov Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | — | Terminated | — | — | — |
NCT03514121CT.gov FPA150 in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03289819CT.gov Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC | — | Completed | — | — | — |
NCT03428802CT.gov Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability | — | Active Not Recruiting | — | — | — |
NCT03225547CT.gov Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer | — | Terminated | — | — | — |
NCT03393845CT.gov Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients | — | Active Not Recruiting | — | — | — |
NCT03197389CT.gov Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer. | — | Completed | — | — | — |
NCT03366844CT.gov Breast Cancer Study of Preoperative Pembrolizumab + Radiation | — | Active Not Recruiting | — | — | — |
NCT03373708CT.gov Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer | — | Unknown | — | — | — |
NCT03222856CT.gov Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes | — | Completed | — | — | — |
NCT03362060CT.gov PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03012230CT.gov Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT03329950CT.gov A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | — | Completed | — | — | — |
NCT03507465CT.gov Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer | — | Unknown | — | — | — |
NCT04659551CT.gov Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients | — | Completed | — | — | — |
NCT03106415CT.gov Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT03237572CT.gov Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT03025035CT.gov Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer | — | Completed | — | — | — |
NCT03095352CT.gov Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease | — | Completed | — | — | — |
NCT03025880CT.gov Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC | — | Completed | — | — | — |
NCT02971761CT.gov Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT03044730CT.gov Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery | — | Unknown | — | — | — |
NCT03051672CT.gov Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC | — | Terminated | — | — | — |
NCT03356860CT.gov Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. | — | Completed | — | — | — |
NCT03051659CT.gov A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer | — | Completed | — | — | — |
NCT07407244CT.gov Immune Tumor Stroma Factors and Pathologic Complete Response After Neoadjuvant Chemotherapy in Early Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02999477CT.gov A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer | — | Completed | — | — | — |
NCT03032107CT.gov A Study Of Pembrolizumab In Combination With Trastuzumab-DM1 | — | Completed | — | — | — |
NCT02971748CT.gov Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy | — | Active Not Recruiting | — | — | — |
NCT02957968CT.gov Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca | — | Active Not Recruiting | — | — | — |
NCT02954874CT.gov Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT01676753CT.gov Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer | — | Completed | — | — | — |
NCT03123770CT.gov Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients | — | Unknown | — | — | — |
NCT02779751CT.gov A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02778685CT.gov Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02789332CT.gov Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency | — | Completed | — | — | — |
NCT03273595CT.gov Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer | — | Unknown | — | — | — |
NCT02730130CT.gov Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients | — | Completed | — | — | — |
NCT02752685CT.gov Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02685059CT.gov Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT02742051CT.gov A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer | — | Completed | — | — | — |
NCT02657889CT.gov Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer | — | Completed | — | — | — |
NCT02624973CT.gov PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial | — | Active Not Recruiting | — | — | — |
NCT02694224CT.gov Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients | — | Unknown | — | — | — |
NCT02692742CT.gov Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia | — | Completed | — | — | — |
NCT02532400CT.gov Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients | — | Terminated | — | — | — |
NCT02646748CT.gov Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | — | Completed | — | — | — |
NCT02628613CT.gov Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations | — | Completed | — | — | — |
NCT02627248CT.gov Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery | — | Unknown | — | — | — |
NCT02535221CT.gov Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer | — | Recruiting | — | — | — |
NCT02447003CT.gov Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086) | — | Completed | — | — | — |
NCT02414269CT.gov Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | — | Active Not Recruiting | — | — | — |
NCT02393248CT.gov Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | — | Terminated | — | — | — |
NCT02315196CT.gov Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02339532CT.gov Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status | — | Completed | — | — | — |
NCT02331251CT.gov Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | — | Terminated | — | — | — |
NCT02934828CT.gov Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer | — | Unknown | — | — | — |
NCT02318901CT.gov Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer | — | Terminated | — | — | — |
NCT02365805CT.gov Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer | — | Completed | — | — | — |
NCT01966471CT.gov A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer | — | Completed | — | — | — |
NCT02842099CT.gov Standard Chemotherapy Followed by Capecitabine as Prolonged Postoperative Adjuvant Treatment for Breast Cancer | — | Unknown | — | — | — |
NCT01996267CT.gov Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 | — | Active Not Recruiting | — | — | — |
NCT02009449CT.gov A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT02980965CT.gov Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer | — | Completed | — | — | — |
NCT02897700CT.gov A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast | — | Recruiting | — | — | — |
NCT02527746CT.gov Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy | — | Completed | — | — | — |
NCT01624441CT.gov Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer | — | Completed | — | — | — |
NCT01593020CT.gov Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 | — | Completed | — | — | — |
NCT01611051CT.gov A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy | — | Completed | — | — | — |
NCT01503905CT.gov Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients | — | Unknown | — | — | — |
NCT01537536CT.gov Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer | — | Completed | — | — | — |
NCT01479036CT.gov Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer | — | Unknown | — | — | — |
NCT01985841CT.gov Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer | — | Terminated | — | — | — |
NCT01501487CT.gov MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I | — | Completed | — | — | — |
NCT01433562CT.gov Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients | — | Completed | — | — | — |
NCT01378533CT.gov The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC | — | Unknown | — | — | — |
NCT01220128CT.gov Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer | — | Terminated | — | — | — |
NCT02119715CT.gov A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy | — | Completed | — | — | — |
NCT01205217CT.gov Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer | — | Withdrawn | — | — | — |
NCT01199432CT.gov Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer | — | Completed | — | — | — |
NCT01314833CT.gov Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy | — | Completed | — | — | — |
NCT01210768CT.gov A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients | — | Unknown | — | — | — |
NCT01134523CT.gov Regimens Comparison for Breast Cancers of Positive Lymph Nodes | — | Unknown | — | — | — |
NCT01006785CT.gov Efficacy and Safety of DLBS1425 in Subjects With Advanced/Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00847444CT.gov Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as Well as Life Style Intervention | — | Unknown | — | — | — |
NCT00841828CT.gov Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients | — | Completed | — | — | — |
NCT00756470CT.gov Phase II Neoadjuvant in Inflammatory Breast Cancer | — | Terminated | — | — | — |
NCT00722293CT.gov A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors | — | Completed | — | — | — |
NCT00830544CT.gov Study of Neoadjuvant Chemotherapy of Breast Cancer | — | Unknown | — | — | — |
NCT00776724CT.gov Tailored Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 2 cm | — | Completed | — | — | — |
NCT00604435CT.gov Neoadjuvant Endostatin and Chemotherapy for Breast Cancer | — | Completed | — | — | — |
NCT00567554CT.gov Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer | — | Completed | — | — | — |
NCT00753207CT.gov Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30 | — | Completed | — | — | — |
NCT00630032CT.gov Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer | — | Completed | — | — | — |
NCT00524303CT.gov Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy. | — | Completed | — | — | — |
NCT00525759CT.gov Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer | — | Completed | — | — | — |
NCT00499603CT.gov Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer | — | Unknown | — | — | — |
NCT00432172CT.gov Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients | — | Completed | — | — | — |
NCT00531973CT.gov A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging | — | Unknown | — | — | — |
NCT01622478CT.gov Validity of Sentinel Lymphnode Biopsy After Neoadjuvant Chemotherapy Cancer Patients With Radiologically Positive Axillary Lymph Nodes | — | Completed | — | — | — |
NCT00398489CT.gov Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery | — | Unknown | — | — | — |
NCT00429299CT.gov Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer | — | Completed | — | — | — |
NCT00322374CT.gov Phase I Combination w/ Epirubicin | — | Completed | — | — | — |
NCT00527449CT.gov Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel | — | Completed | — | — | — |
NCT00462696CT.gov MRI in Evaluating Early Response to Chemotherapy in Women With Infiltrating Breast Cancer | — | Completed | — | — | — |
NCT00193206CT.gov Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer | — | Completed | — | — | — |
NCT02392845CT.gov A Pilot Dose Escalation Trial of a Densified Chemotherapy Association of Docetaxel and Epirubicin Driven by Mathematical Modeling in Metastatic Breast Cancer Patients: The MODEL1 Study | — | Completed | — | — | — |
NCT00286819CT.gov Dose Density FU 75 and FU 90 as Adjuvant Therapy for Early Breast Cancer | — | Completed | — | — | — |
NCT00617370CT.gov Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility | — | Completed | — | — | — |
NCT00196872CT.gov A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN) | — | Completed | — | — | — |
NCT00309920CT.gov Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer | — | Unknown | — | — | — |
NCT00311636CT.gov Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery | — | Completed | — | — | — |
NCT00431795CT.gov Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00251329CT.gov Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before Surgery | — | Unknown | — | — | — |
NCT00053911CT.gov Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer | — | Terminated | — | — | — |
NCT00544232CT.gov Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE) | — | Completed | — | — | — |
NCT00795899CT.gov Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO) | — | Completed | — | — | — |
NCT01222052CT.gov 6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients | — | Unknown | — | — | — |
NCT00378313CT.gov A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer | — | Completed | — | — | — |
NCT00047099CT.gov Combination Chemotherapy in Treating Women With Breast Cancer | — | Completed | — | — | — |
NCT00014222CT.gov Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer | — | Completed | — | — | — |
NCT00668616CT.gov Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph Nodes | — | Completed | — | — | — |
NCT00004237CT.gov Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast Cancer | — | Completed | — | — | — |
NCT00003893CT.gov Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer | — | Completed | — | — | — |
NCT00002784CT.gov High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer | — | Completed | — | — | — |
NCT00002870CT.gov High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Locally Recurrent or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00097383CT.gov Study of Alimta and Epirubicin Administered in Patients With Locally Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Epirubicin (this asset) | Ohio State University Comprehensive Cancer Center | Approved | BB · 67 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Oxaliplatin | Beijing Biostar Pharmaceuticals Co., Ltd. | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Epirubicin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Inflammatory Breast Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Epirubicin in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/epirubicin-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →